{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:12:53Z","timestamp":1790403173603,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.hoc.2016.05.007","type":"journal-article","created":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T22:17:30Z","timestamp":1475187450000},"page":"1099-1114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy"],"prefix":"10.1016","volume":"30","author":[{"given":"Allison P.","family":"Wheeler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gailani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.hoc.2016.05.007_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1538-7836.2007.02500.x","article-title":"The central role of thrombin in hemostasis","volume":"5","author":"Crawley","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/ATVBAHA.115.303397","article-title":"Overview of the new oral anticoagulants: opportunities and challenges","volume":"35","author":"Yeh","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.hoc.2016.05.007_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of heparin and related drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2016.05.007_bib4","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulation therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.hoc.2016.05.007_bib5","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1182\/blood-2007-10-120543","article-title":"Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents","volume":"111","author":"Crowther","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib6","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis","volume":"124","author":"Chai-Adisaksopha","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/joim.12430","article-title":"Factor XII: a novel target for safe prevention of thrombosis and inflammation","volume":"278","author":"Kenne","year":"2015","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.hoc.2016.05.007_bib8","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.drudis.2014.04.018","article-title":"Inhibition of factor XI activity as a promising antithrombotic strategy","volume":"19","author":"Chen","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.hoc.2016.05.007_bib9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.13005","article-title":"Factor XI and contact activation as targets for antithrombotic therapy","volume":"13","author":"Gailani","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/202498a0","article-title":"An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier","volume":"202","author":"Macfarlane","year":"1964","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2016.05.007_bib11","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1126\/science.145.3638.1310","article-title":"Waterfall sequence for intrinsic blood coagulation","volume":"145","author":"Davie","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.hoc.2016.05.007_bib12","series-title":"Hematology: basic principles and practice","first-page":"1971","article-title":"Rare coagulation factor deficiencies","author":"Gailani","year":"2013"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2016.05.007_bib13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.thromres.2012.02.017","article-title":"Tissue factor and factor VIIa \u2013 hemostasis and beyond","volume":"129","author":"Wolberg","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.hoc.2016.05.007_bib14","series-title":"Hematology: basic principles and practice","first-page":"1940","article-title":"Hemophilia A and B","author":"Carcao","year":"2013"},{"key":"10.1016\/j.hoc.2016.05.007_bib15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1055\/s-0033-1353420","article-title":"Congenital factor XI deficiency: an update","volume":"39","author":"Duga","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 4","key":"10.1016\/j.hoc.2016.05.007_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/hae.12402","article-title":"Rare bleeding disorders \u2013 bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency","volume":"20","author":"James","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.hoc.2016.05.007_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev.med.46.1.103","article-title":"Tissue factor pathway inhibitor and the revised theory of coagulation","volume":"46","author":"Broze","year":"1995","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.hoc.2016.05.007_bib18","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1213\/ane.0b013e31819bceb1","article-title":"The role of tissue factor and factor VIIa in hemostasis","volume":"108","author":"Mackman","year":"2009","journal-title":"Anesth Analg"},{"key":"10.1016\/j.hoc.2016.05.007_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1101\/sqb.2009.74.001","article-title":"Step-by-step evolution of vertebrate coagulation","volume":"74","author":"Doolittle","year":"2009","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"10.1016\/j.hoc.2016.05.007_bib20","series-title":"Mouse models of coagulation factor deficiencies, in animal models of diseases: translational medicine perspective for drug discovery and development","first-page":"67","author":"McManus","year":"2012"},{"key":"10.1016\/j.hoc.2016.05.007_bib21","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1538-7836.2008.03143.x","article-title":"Evolution of the contact phase of vertebrate blood coagulation","volume":"6","author":"Ponczek","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib22","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2009-09-199182","article-title":"Structure and function of factor XI","volume":"115","author":"Emsley","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib23","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.1016\/S0021-9258(20)89453-8","article-title":"Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces","volume":"266","author":"Naito","year":"1991","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.hoc.2016.05.007_bib24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1126\/science.1652157","article-title":"Factor XI activation in a revised model of blood coagulation","volume":"253","author":"Gailani","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.hoc.2016.05.007_bib25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood-2010-10-312983","article-title":"Activation of factor XI by products of prothrombin activation","volume":"118","author":"Matafonov","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2016.05.007_bib26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jth.13235","article-title":"Contact system revisited: an interface between inflammation, coagulation, and innate immunity","volume":"14","author":"Long","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/jth.13194","article-title":"The contact activation and kallikrein\/kinin systems: pathophysiologic and physiologic activities","volume":"14","author":"Schmaier","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1160\/TH07-01-0051","article-title":"The dual role of the contact system in bacterial infectious disease","volume":"98","author":"Frick","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib29","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1038\/sj.emboj.7601422","article-title":"The contact system \u2013 a novel branch of innate immunity generating antibacterial peptides","volume":"25","author":"Frick","year":"2006","journal-title":"EMBO J"},{"key":"10.1016\/j.hoc.2016.05.007_bib30","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood.V90.10.3962","article-title":"A\u00a0coagulation factor IX-deficient mouse model for human hemophilia B","volume":"90","author":"Lin","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice","volume":"3","author":"Wang","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.20050664","article-title":"Defective thrombus formation in mice lacking coagulation factor XII","volume":"202","author":"Renn\u00e9","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.hoc.2016.05.007_bib33","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","article-title":"A\u00a0role for factor XIIa-mediated factor XI activation in thrombus formation in\u00a0vivo","volume":"116","author":"Cheng","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib34","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.cell.2009.11.001","article-title":"Platelet polyphosphates are proinflammatory and procoagulant mediators in\u00a0vivo","volume":"139","author":"M\u00fcller","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2016.05.007_bib35","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1182\/blood-2011-05-355248","article-title":"Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased bleeding","volume":"188","author":"Revenko","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib36","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1160\/TH11-10-0682","article-title":"Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait","volume":"107","author":"Bird","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib37","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2014-01-550285","article-title":"Reduced thrombosis in Klkb1-\/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor","volume":"125","author":"Stavrou","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib38","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1182\/blood-2007-06-092338","article-title":"Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis","volume":"111","author":"Merkulov","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib39","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood-2003-01-0324","article-title":"Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates","volume":"102","author":"Gruber","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib40","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2008-06-163675","article-title":"Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI","volume":"113","author":"Tucker","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib41","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","article-title":"Factor XII inhibition reduces thrombus formation in a primate thrombosis model","volume":"123","author":"Matafonov","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib42","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/ATVBAHA.113.301282","article-title":"Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates","volume":"33","author":"Crosby","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.hoc.2016.05.007_bib43","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3324\/haematol.2009.005769","article-title":"Factor IX and deep vein thrombosis","volume":"94","author":"Lowe","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2016.05.007_bib44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000083835","article-title":"Elevated clotting factor levels and venous thrombosis","volume":"33","author":"Bertina","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.hoc.2016.05.007_bib45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.1999.01317.x","article-title":"Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Study","volume":"105","author":"Rumley","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.05.007_bib46","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/euhj.2001.3237","article-title":"Von Willebrand factor and coronary heart disease: prospective study and meta-analysis","volume":"23","author":"Whincup","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hoc.2016.05.007_bib47","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0002-9343(02)01345-1","article-title":"Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE)","volume":"113","author":"Tsai","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.hoc.2016.05.007_bib48","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1538-7836.2007.02818.x","article-title":"ABO (H) blood groups and vascular disease: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib49","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V95.12.3678.012k45_3678_3682","article-title":"High levels of factor IX increase the risk of venous thrombosis","volume":"95","author":"van Hylckama Vlieg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib50","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1309\/AJCPAGOR4Q2IIKUG","article-title":"Elevated factor IX activity is associated with an increased odds ratio for both arterial and venous thrombotic events","volume":"140","author":"Heikal","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hoc.2016.05.007_bib51","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2005-12-023697","article-title":"Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII","volume":"108","author":"Doggen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib52","first-page":"67","article-title":"Procoagulant factors and the risk of myocardial infarction in young women","volume":"77","author":"Tanis","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hoc.2016.05.007_bib53","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000297966","article-title":"Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"29","author":"Suri","year":"2010","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.hoc.2016.05.007_bib54","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(03)14021-4","article-title":"Decreased mortality of ischaemic heart disease among carriers of haemophilia","volume":"362","author":"Sramek","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2016.05.007_bib55","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.05.007_bib56","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2009-05-219915","article-title":"Coagulation factors IX through XIII and the risk of future venous thrombosis: the longitudinal investigation of thromboembolism etiology","volume":"114","author":"Cushman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib57","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib58","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/QC259F09UNMKVP0R","article-title":"Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events","volume":"126","author":"Yang","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hoc.2016.05.007_bib59","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.943738","article-title":"Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) case-control study","volume":"122","author":"Siegerink","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.hoc.2016.05.007_bib60","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0049-3848(02)00190-1","article-title":"Elevated levels of factor XI are associated with cardiovascular disease in women","volume":"107","author":"Berliner","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.hoc.2016.05.007_bib62","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1111\/j.1538-7836.2007.02687.x","article-title":"The plasma kallikrein-kinin system and risk of cardiovascular disease in men","volume":"5","author":"Govers-Riemslag","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib63","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1538-7836.2003.00195.x","article-title":"Inherited factor XI deficiency confers no protection against acute myocardial infarction","volume":"1","author":"Salomon","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib64","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/jth.13045","article-title":"Hypercoagulability and the risk of myocardial infarction and ischemic stroke in young woman","volume":"13","author":"Siegerink","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib65","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1055\/s-0037-1614368","article-title":"Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency\u2013a study on 73 subjects from 14 Swiss families","volume":"82","author":"Zeerleder","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib66","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2141.1994.tb04937.x","article-title":"John Hageman's factor and deep-vein thrombosis: Leiden Thrombophilia Study","volume":"87","author":"Koster","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.05.007_bib67","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1538-7836.2007.02530.x","article-title":"Evidence of a U-shaped association between factor XII activity and overall survival","volume":"5","author":"Endler","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib68","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0003-4975(97)01340-4","article-title":"Complement and contact activation during cardiovascular operations in infants","volume":"65","author":"Sonntag","year":"1998","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.hoc.2016.05.007_bib69","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0162-3109(99)00067-3","article-title":"FXII levels, FXIIa-like activities and kallikrein activities in normal subjects and patients undergoing cardiac surgery","volume":"45","author":"Wendel","year":"1999","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.hoc.2016.05.007_bib70","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0022-5223(19)34156-X","article-title":"Blood activation during neonatal extracorporeal life support","volume":"105","author":"Pl\u00f6tz","year":"1993","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.hoc.2016.05.007_bib71","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/01.ATV.0000259363.91070.f1","article-title":"Factor IXa inhibitors as novel anticoagulants","volume":"27","author":"Howard","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.hoc.2016.05.007_bib72","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1538-7836.2007.02872.x","article-title":"Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study","volume":"6","author":"Eriksson","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib73","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1161\/ATVBAHA.110.203117","article-title":"Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism","volume":"30","author":"Eikelboom","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.hoc.2016.05.007_bib74","doi-asserted-by":"crossref","first-page":"A1886","DOI":"10.1182\/blood.V106.11.1886.1886","article-title":"TTP889, a novel orally active partial inhibitor of FIXa inhibits clotting in two a\/v shunt models without prolonging bleeding times","volume":"106","author":"Rothlein","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib75","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1161\/ATVBAHA.115.300131","article-title":"Modulation of the coagulation cascade using aptamers","volume":"35","author":"Woodruff","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.hoc.2016.05.007_bib76","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.668434","article-title":"First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity","volume":"114","author":"Dyke","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hoc.2016.05.007_bib77","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1538-7836.2008.02932.x","article-title":"A\u00a0randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor","volume":"6","author":"Chan","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib78","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCULATIONAHA.109.927756","article-title":"First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention","volume":"122","author":"Cohen","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.hoc.2016.05.007_bib79","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/eurheartj\/ehs232","article-title":"A\u00a0Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial","volume":"34","author":"Povsic","year":"2013","journal-title":"Eur Heart J"},{"issue":"10016","key":"10.1016\/j.hoc.2016.05.007_bib80","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(15)00515-2","article-title":"Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomized clinical trial","volume":"387","author":"Lincoff","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2016.05.007_bib81","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib82","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2011-10-387134","article-title":"Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys","volume":"119","author":"Younis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib83","doi-asserted-by":"crossref","first-page":"A209","DOI":"10.1182\/blood.V118.21.209.209","article-title":"ISIS-FXIRx, a novel and specific antisense inhibitor of factor XI, caused significant reduction in FXI antigen and activity and increased aPTT without causing bleeding in healthy volunteers","volume":"118","author":"Liu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib84","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.05.007_bib85","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/j.1538-7836.2010.04021.x","article-title":"A\u00a0dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty","volume":"8","author":"Fuji","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib86","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1160\/TH09-11-0771","article-title":"Tissue factor and thrombosis: the clot starts here","volume":"104","author":"Owens","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2016.05.007_bib87","doi-asserted-by":"crossref","first-page":"222ra17","DOI":"10.1126\/scitranslmed.3006804","article-title":"A\u00a0factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk","volume":"6","author":"Larsson","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hoc.2016.05.007_bib88","first-page":"247","article-title":"The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities","volume":"3","author":"Worm","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.hoc.2016.05.007_bib89","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.05.007_bib90","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/asheducation-2014.1.52","article-title":"Future prospects for contact factors as therapeutic targets","volume":"2014","author":"Gailani","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2016.05.007_bib91","doi-asserted-by":"crossref","first-page":"f5440","DOI":"10.1136\/bmj.f5440","article-title":"Secondary prevention of venous thromboembolism","volume":"347","author":"Schulman","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.hoc.2016.05.007_bib92","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood-2013-12-512681","article-title":"Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism","volume":"123","author":"Kearson","year":"2013","journal-title":"Blood"},{"issue":"Suppl 4","key":"10.1016\/j.hoc.2016.05.007_bib93","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2516.2004.00992.x","article-title":"New observations on factor XI deficiency","volume":"10","author":"Salomon","year":"2004","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2016.05.007_bib94","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816300594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816300594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:04:24Z","timestamp":1760184264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858816300594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0889858816300594"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2016.05.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2016.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}